Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278446 | 0.86 | TMEM97 (0.30) | — | |
| SCHEMBL3277051 | 0.72 | — | — | |
| SCHEMBL3115401 | 0.66 | ALDH1A1 (0.35) | ALDH1A1HPGDTSHRCYP3A4CYP2C9 | |
| SCHEMBL13120886 | 0.66 | ACHE (0.37) | ALDH1A1HPGDTSHRCYP3A4CYP2C9 | |
| SCHEMBL3115405 | 0.66 | ALDH1A1 (0.44) | ALDH1A1HPGDTSHRMAPT | |
| SCHEMBL5258931 | 0.65 | ACHE (0.58) | ACHE | |
| SCHEMBL14127397 | 0.65 | ALDH1A1 (0.32) | ALDH1A1HPGDTSHR | |
| SCHEMBL3275975 | 0.65 | — | — | |
| SCHEMBL1033055 | 0.64 | ELANE (0.51) | CYP3A4ACHE | |
| SCHEMBL17183945 | 0.64 | L3MBTL1 (0.38) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7696230-B2 | Drugs for chronic pains | NICOX S.A. (FR) | 2010-04-13 | — | — | US | disclosed |
| US-20070161576-A1 | Drugs for chronic pains | NICOX S.A. | 2007-07-12 | — | — | US | disclosed |
| EP-1417165-A2 | DRUGS FOR CHRONIC PAINS | Nicox S.A. (FR) | 2004-05-12 | — | — | EP | disclosed |
| WO-2003000643-A1 | NITRATE ESTER DERIVATIVES USEFUL FOR PREPARING DRUGS FOR EPILEPSY | NICOX S.A. (FR) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000642-A2 | DRUGS FOR CHRONIC PAINS | NICOX S.A. (FR) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161576-A1 | Drugs for chronic pains | OPRD1, OPRL1, OPRK1 | ALDH1A1 144/4885HPGD 245/4885TSHR 3022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.